Cargando…

Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer

Anaemia is a common haematologic disorder in patients with cancer and has a multifactorial aetiology, including the effects of the malignancy itself and residual effects from previous therapy. Novel erythropoiesis stimulating protein (NESP, darbepoetin alfa), a protein with additional sialic acid co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, R E, Jaiyesimi, I A, Meza, L A, Tchekmedyian, N S, Chan, D, Griffith, H, Brosman, S, Bukowski, R, Murdoch, M, Rarick, M, Saven, A, Colowick, A B, Fleishman, A, Gayko, U, Glaspy, J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2001
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363901/ https://www.ncbi.nlm.nih.gov/pubmed/11308271 http://dx.doi.org/10.1054/bjoc.2001.1749

Ejemplares similares

A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy
por: Glaspy, J, et al.
Publicado: (2001)

Development and characterization of novel erythropoiesis stimulating protein (NESP)
por: Egrie, J C, et al.
Publicado: (2001)

Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report
por: Heatherington, A C, et al.
Publicado: (2001)

A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer
por: Smith, R E, et al.
Publicado: (2003)

Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy
por: Glaspy, J A, et al.
Publicado: (2002)

Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP(®)) Biosimilar, to Those of NESP(®) After a Single Subcutaneous or Intravenous Administration to Healthy Subjects
por: Jeon, Inseung, et al.
Publicado: (2021)

Budget impact analysis on erythropoiesis–stimulating agents use for the management of chemotherapy-induced anaemia in Greece
por: Nikolaidi, Eleftheria, et al.
Publicado: (2013)

Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes
por: Glaspy, J, et al.
Publicado: (2010)

Antisense Activity across the Nesp Promoter is Required for Nespas-Mediated Silencing in the Imprinted Gnas Cluster
por: Tibbit, Charlotte J., et al.
Publicado: (2015)

Very small deletions within the NESP55 gene in pseudohypoparathyroidism type 1b
por: Rezwan, Faisal I, et al.
Publicado: (2015)

Combination treatment with an erythropoiesis-stimulating agent and intravenous iron alleviates anaemia in patients with hereditary haemorrhagic telangiectasia
por: Cherif, Honar, et al.
Publicado: (2014)

Cost-Minimisation Analysis of Erythropoiesis-Stimulating Agents in the Treatment of Anaemia in Dialysed Patients: A Pilot Study
por: Darsonval, Astrid, et al.
Publicado: (2017)

Non-erythropoiesis-stimulating agent, non-iron therapies for the management of anaemia: protocol for a scoping review
por: Devlin, Paula, et al.
Publicado: (2022)

NESP55, a novel chromogranin-like peptide, is expressed in endocrine tumours of the pancreas and adrenal medulla but not in ileal carcinoids
por: Jakobsen, A-M, et al.
Publicado: (2003)

Maternal inheritance of the Gnas cluster mutation Ex1A-T affects size, implicating NESP55 in growth
por: Eaton, Sally A., et al.
Publicado: (2013)

A phase II study of the bispecific antibody MDX-H210 (anti-HER2 × CD64) with GM-CSF in HER2+ advanced prostate cancer
por: James, N D, et al.
Publicado: (2001)

Altitude Pre-Acclimatization with an Erythropoiesis-Stimulating Agent
por: Heldeweg, Micah L. A., et al.
Publicado: (2023)

Introduction
por: Glaspy, J
Publicado: (2001)

Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data
por: Bohlius, J, et al.
Publicado: (2014)

Pharmacovigilance in practice: erythropoiesis-stimulating agents
por: Hedenus, Michael, et al.
Publicado: (2014)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia
por: Pashos, Chris L., et al.
Publicado: (2011)

Networking erythropoiesis
por: Kerenyi, Marc A., et al.
Publicado: (2010)

Erythropoiesis stimulating agents: approaches to modulate activity
por: Sinclair, Angus M
Publicado: (2013)

Mutation analysis of the Fanconi anaemia A gene in breast tumours with loss of heterozygosity at 16q24.3
por: Cleton-Jansen, A-M, et al.
Publicado: (1999)

Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment
por: Liu, Lanting, et al.
Publicado: (2020)

Long- Versus Short-Acting Erythropoiesis-Stimulating Agent Type and Mortality
por: Karaboyas, Angelo, et al.
Publicado: (2020)

Use of erythropoiesis-stimulating agents in obese hemodialysis patients
por: Park, Sun-Hee
Publicado: (2018)

Treatment of renal anemia: Erythropoiesis stimulating agents and beyond
por: Biggar, Patrick, et al.
Publicado: (2017)

Tips for erythropoiesis-stimulating agent treatment of renal anemia
por: Tomosugi, Naohisa, et al.
Publicado: (2019)

Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19
por: Fishbane, Steven, et al.
Publicado: (2020)

The effects of chronic glucorticoid stimulation on erythropoiesis in Cushing syndrome
por: Strouboulis, John, et al.
Publicado: (2022)

Stimulation of erythropoiesis by the non-steroidal anti-androgen nilutamide in men with prostate cancer: evidence for an agonistic effect?
por: Decensi, A., et al.
Publicado: (1994)

Neuroimaging in Former Preterm Children Who Received Erythropoiesis Stimulating Agents
por: Phillips, Authors: John, et al.
Publicado: (2017)

A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia
por: Ludwig, Heinz, et al.
Publicado: (2014)

A nano erythropoiesis stimulating agent for the treatment of anemia and associated disorders
por: Das, Monojit, et al.
Publicado: (2022)

Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy
por: Barrett-Lee, P J, et al.
Publicado: (2000)

Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis
por: Honda, Hirokazu, et al.
Publicado: (2016)

The Use of Darbepoetin to Stimulate Erythropoiesis in the Treatment of Anemia of Chronic Kidney Disease in Dogs
por: Fiocchi, E.H., et al.
Publicado: (2017)

Combined effect of metformin and gallic acid on inflammation, antioxidant status, endoplasmic reticulum (ER) stress and glucose metabolism in fructose-fed streptozotocin-induced diabetic rats
por: Obafemi, Tajudeen O., et al.
Publicado: (2021)

Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer
por: Melosky, B.L.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_uo0kphvmq7tokjhl2lbtqfooml